Evidence map›Paper›PMID 27401890›Full record

ArticleThe oncologist2016

Cancer Control in Central and Eastern Europe: Current Situation and Recommendations for Improvement.

Eduard Vrdoljak, Gyorgy Bodoky, Jacek Jassem, Razvan A Popescu, Jozef Mardiak, Robert Pirker, Tanja Čufer, Semir Bešlija, Alexandru Eniu, Vladimir Todorović and 7 more

Abstract read
In one paragraph

Article in The oncologist, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. The state of gynecologic radiation therapy in low- and middle-income countries.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2022
    Review
  13. Observational
  14. Article
  15. Article
  16. Is it too expensive to fight cancer? Analysis of incremental costs and benefits of the Croatian National Plan Against Cancer.The European journal of health economics : HEPAC : health economics in prevention and care · 2021
    Article
  17. Review
  18. Lung cancer biomarker testing: perspective from Europe.Translational lung cancer research · 2020
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Eduard VrdoljakDepartment of Oncology, Clinical Hospital Center Split, School of Medicine, University of Split, Split, Croatia edo.vrdoljak@gmail.com.
Gyorgy BodokyDepartment of Oncology, St. László Teaching Hospital, Budapest, Hungary.
Jacek JassemMedical University of Gdańsk, Gdańsk, Poland.
Razvan A PopescuDepartment of Medical Oncology, Tumor Center Aarau, Aarau, Switzerland.
Jozef Mardiak2nd Department of Oncology, Faculty of Medicine, Comenius University, Bratislava, Slovak Republic National Cancer Institute, Bratislava, Slovak Republic.
Robert PirkerDivision of Oncology and Hematology, Department of Medicine I, Medical University of Vienna, Austria.
Tanja ČuferUniversity Clinic Golnik, Golnik, Slovenia.
Semir BešlijaInstitute of Oncology, Clinical Center, University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
Alexandru EniuDepartment of Breast Tumors, Cancer Institute "Prof. Dr. I. Chiricuta" Cluj-Napoca, Romania.
Vladimir TodorovićOncology and Radiotherapy Clinic, Clinical Centre of Montenegro, Podgorica, Montenegro.
Kateřina KubáčkováDepartment of Oncology, University Hospital Motol, Charles University, Prague, Czech Republic.
Galia KurtevaNational Hospital of Oncology, Sofia, Bulgaria.
Zorica TomaševićDaily Chemotherapy Hospital, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia.
Agim SallakuOncology Institute, University Hospital Center Mother Teresa, Tirana, Albania.
Snezhana SmichkoskaInstitute of Radiotherapy and Oncology, Skopje, Macedonia.
Žarko BajićBiometrika Healthcare Research, Zagreb, Croatia.
Branimir I ŠikićOncology Division, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

: The incidence of many cancers is higher in Western European (WE) countries, but mortality is frequently higher in Central and Eastern European (CEE) countries. A panel of oncology leaders from CEE countries participating in the South Eastern European Research Oncology Group (SEEROG) was formed in 2015, aiming to analyze the current status and trends of oncology care in CEE and to propose recommendations leading to improved care and outcomes. The SEEROG panel, meeting during the 11th Central European Oncology Congress, proposed the following: (a) national cancer control plans (NCCPs) required in all CEE countries, defining priorities in cancer care, including finance allocation considering limited health care budgets; (b) national cancer registries, describing in detail epidemiological trends; (c) efforts to strengthen comprehensive cancer centers; (d) that multidisciplinary care should be mandated by the NCCPs; (e) that smaller hospitals should be connected to multidisciplinary tumor boards via the Internet, providing access to specialized expertise; (f) nationwide primary prevention programs targeting smoking, obesity, and alcohol consumption and centrally evaluated secondary prevention programs for cervical, colorectal, and breast cancers; (g) prioritize education for all involved in cancer care, including oncology nurses, general practitioners, and palliative care providers; (h) establish outpatient care in day hospitals to reduce costs associated with the current inpatient model of care in CEE countries and to improve patients' quality of life; (i) long-term pharmacoeconomic evaluations of new therapies in CEE countries; (j) increase national oncology budgets in view of the higher mortality rates in CEE compared with WE countries; and (k) CEE countries urgently need help from the European Union to increase and monitor overall investment in cancer care. IMPLICATIONS FOR PRACTICE: Significant differences in cancer incidence and mortality have been observed between European countries. While the incidence of many cancer types is higher in Western European (WE) countries, the mortality is generally higher in Central and Eastern Europe (CEE). The primary purpose of this review was to describe the current status and trends of oncology care in the CEE region, to raise awareness among physicians, regulators, and payers, and to propose the most needed changes in order to make the oncology care in CEE closer to the WE standards.

Indexed as

Early Detection of CancerEconomics, PharmaceuticalEuropeIncidenceNeoplasmsRegistriesCancerHealth care budgetIncidenceMortalityOncologySouth-East Europe

Identifiers

PMID27401890
PMCPMC5061531

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.